Who was studied, and how
Four numbers in the abstract
Where each one falls
Where it lands on the map
What it changes
Among 8 other studies
237,870people with cardiovascular disease, in this paper
Among individuals with baseline LDL-C values of 100 mg/dL or higher, the trial randomly assignedassigned by chance
Statins
Control (implied)
May have raised major heart events+31.0
randomised · one subgroupThe trial randomly assignedassigned by chance
Ezetimibe
Control (implied)
Raised major heart events+18.0
randomisedthe abstract, start to end
… needed to treat to benefit (NNTB) 31, 95% confidence interval (CI) …
… were effective in reducing MACE (NNTB 18, 95% CI 11-41, and NNTB 18, 95% CI 16-24).
… [number needed to treat to harm (NNTH) 41, 95% CI 80-26].
← favours treatmentfavours comparator →
could be chanceMACEStatins vs Control (implied), in individuals with baseline LDL-C values of 100 mg/dL or higher
NNT 3125.0–37.0
MACEEzetimibe vs Control (implied)
NNT 1811.0–41.0
MACEPCSK9 inhibitors vs Control (implied)
NNT 1816.0–24.0
Injection-site reactionsPCSK9 inhibitors vs Control (implied)
NNT 4126.0–80.0
StatinsPCSK9 inhibitorsOther lipid agentsCardiovascular eventsAdverse events & safety
Other lipid agents × cardiovascular eventshelps?settled
unlikelylikely
0.80not counted
PCSK9 inhibitors × adverse events & safetyharms?mixed
unlikelylikely
0.00not counted
PCSK9 inhibitors × cardiovascular eventshelps?settled
unlikelylikely
1.00not counted
← favours treatmentfavours comparator →
1 / 6